MA46973A - Polymorphes de sépiaptérine et leurs sels - Google Patents

Polymorphes de sépiaptérine et leurs sels

Info

Publication number
MA46973A
MA46973A MA046973A MA46973A MA46973A MA 46973 A MA46973 A MA 46973A MA 046973 A MA046973 A MA 046973A MA 46973 A MA46973 A MA 46973A MA 46973 A MA46973 A MA 46973A
Authority
MA
Morocco
Prior art keywords
sepiapterin
polymorphs
salts
sepiapterin polymorphs
Prior art date
Application number
MA046973A
Other languages
English (en)
Inventor
Daniel E Levy
Original Assignee
Censa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Censa Pharmaceuticals Inc filed Critical Censa Pharmaceuticals Inc
Publication of MA46973A publication Critical patent/MA46973A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA046973A 2016-11-29 2017-11-28 Polymorphes de sépiaptérine et leurs sels MA46973A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29
US201762546390P 2017-08-16 2017-08-16

Publications (1)

Publication Number Publication Date
MA46973A true MA46973A (fr) 2019-10-09

Family

ID=62241930

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046973A MA46973A (fr) 2016-11-29 2017-11-28 Polymorphes de sépiaptérine et leurs sels

Country Status (14)

Country Link
US (4) US11072614B2 (fr)
EP (1) EP3548497A4 (fr)
JP (3) JP7148533B2 (fr)
KR (3) KR102561697B1 (fr)
CN (2) CN110248948B (fr)
AU (3) AU2017366879C1 (fr)
BR (1) BR122021026889A8 (fr)
CA (1) CA3043502A1 (fr)
CO (1) CO2019006018A2 (fr)
IL (2) IL301470A (fr)
MA (1) MA46973A (fr)
MX (3) MX386520B (fr)
NZ (1) NZ753504A (fr)
WO (1) WO2018102315A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2562176B1 (fr) 2010-04-22 2018-08-15 Nihon University Agent médicinal et boisson/aliment pour prévenir un dysfonctionnement cérébral et améliorer ses symptômes
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
EP3548497A4 (fr) * 2016-11-29 2020-09-02 Censa Pharmaceuticals Inc. Polymorphes de sépiaptérine et leurs sels
EP3675863A4 (fr) * 2017-09-01 2021-01-27 PTC Therapeutics MP, Inc. Composition pharmaceutique comprenant de la sépiaptérine et ses utilisations
EP3807279B1 (fr) * 2018-05-30 2025-12-31 PTC Therapeutics MP, Inc. Sels pharmaceutiquement acceptables de sépiaptérine avec une stabilité améliorée
MD3801536T2 (ro) 2018-05-30 2024-11-30 Ptc Therapeutics Mp Inc Administrarea sepiapterinei fără alimente pentru utilizare într-o metodă de creștere a expunerii plasmatice a sepiapterinei
BR112020024329A2 (pt) 2018-05-30 2021-02-23 Ptc Therapeutics Mp, Inc. composições e métodos para aumentar exposição de plasma de tetra-hidrobiopterin
FI4009978T3 (fi) 2019-08-05 2024-11-01 Ptc Therapeutics Mp Inc Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon
US20220362249A1 (en) 2019-09-25 2022-11-17 Ptc Therapeutics Mp, Inc. Methods for treating hyperphenylalaninemia
US20230110351A1 (en) 2020-01-24 2023-04-13 Ptc Therapeutics Mp, Inc. Methods for treating parkinson's disease with sepiapterin
WO2022173823A1 (fr) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Procédés de traitement de la covid-19 avec de la sépiaptérine
AU2022221345A1 (en) 2021-02-09 2023-09-07 Ptc Therapeutics Mp, Inc. Methods for treating glioblastomas with sepiapterin
US20250041305A1 (en) 2021-09-29 2025-02-06 Ptc Therapeutics, Inc. Pharmaceutical composition of sepiapterin
WO2024249602A2 (fr) * 2023-05-30 2024-12-05 The Board Of Trustees Of The Leland Stanford Junior University Syndrome des jambes sans repos (rls) et mouvements périodiques des jambes pendant le sommeil (plms) : biomarqueur et cible médicamenteuse
CN117205164B (zh) * 2023-09-30 2024-07-26 山东新时代药业有限公司 一种盐酸沙丙蝶呤片剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5753656A (en) 1994-08-05 1998-05-19 Suntory Limited Method for treating spinocerebellar degeneration
AU727445B2 (en) 1995-08-18 2000-12-14 Donald W Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
US20070049599A1 (en) 2003-10-31 2007-03-01 Altana Pharma Ag Use of bh4 for the treatment of respiratory diseases
CA2678125C (fr) 2003-11-17 2014-10-14 Merck Eprova Ag Formes cristallines de dihydrochlorure de (6r)-l-erythro-tetrahydrobiopterine
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
WO2006055511A2 (fr) * 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Formule stable de comprimes
JP2008523090A (ja) 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
KR101277074B1 (ko) 2005-04-28 2013-06-25 다이이찌 산쿄 가부시키가이샤 히드라존 유도체의 제조방법
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
HRP20220188T3 (hr) 2007-04-11 2022-04-29 Biomarin Pharmaceutical Inc. Načini primjene tetrahidrobiopterina, povezani pripravci i postupci mjerenja
UA103189C2 (ru) 2008-03-10 2013-09-25 Такеда Фармасьютикал Компани Лимитед Кристаллическая форма бензимидазольного соединения
ES2736730T3 (es) * 2008-08-12 2020-01-07 Orpha Swiss Gmbh Forma de administración farmacéutica que contiene tetrahidrobiopterina
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
CA2771432A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composes d'oximes heterocycliques
EP2562176B1 (fr) 2010-04-22 2018-08-15 Nihon University Agent médicinal et boisson/aliment pour prévenir un dysfonctionnement cérébral et améliorer ses symptômes
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CN103458900A (zh) 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US9181254B2 (en) * 2012-05-07 2015-11-10 Shiratori Pharmaceutical Co., Ltd. Method for producing sepiapterin and tetrahydrolactoylpterin
AU2017286544B2 (en) 2016-06-13 2022-10-20 Meharry Medical College Modulation of the nitric oxide synthase pathway for oral health
EP3490536A1 (fr) 2016-07-29 2019-06-05 Dipharma S.A. Trousse de composition pharmaceutique comprenant du dichlorhydrate de saproptérine
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
EP3548497A4 (fr) 2016-11-29 2020-09-02 Censa Pharmaceuticals Inc. Polymorphes de sépiaptérine et leurs sels
TWI765936B (zh) 2016-11-29 2022-06-01 美商東京威力科創Ｆｓｉ股份有限公司 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
EP3675863A4 (fr) 2017-09-01 2021-01-27 PTC Therapeutics MP, Inc. Composition pharmaceutique comprenant de la sépiaptérine et ses utilisations
BR112020024329A2 (pt) 2018-05-30 2021-02-23 Ptc Therapeutics Mp, Inc. composições e métodos para aumentar exposição de plasma de tetra-hidrobiopterin
MD3801536T2 (ro) 2018-05-30 2024-11-30 Ptc Therapeutics Mp Inc Administrarea sepiapterinei fără alimente pentru utilizare într-o metodă de creștere a expunerii plasmatice a sepiapterinei
EP3807279B1 (fr) 2018-05-30 2025-12-31 PTC Therapeutics MP, Inc. Sels pharmaceutiquement acceptables de sépiaptérine avec une stabilité améliorée
FI4009978T3 (fi) 2019-08-05 2024-11-01 Ptc Therapeutics Mp Inc Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon
US20220362249A1 (en) 2019-09-25 2022-11-17 Ptc Therapeutics Mp, Inc. Methods for treating hyperphenylalaninemia

Also Published As

Publication number Publication date
KR20250051124A (ko) 2025-04-16
BR122021026889A8 (pt) 2022-11-22
WO2018102315A8 (fr) 2018-09-07
NZ753504A (en) 2025-10-31
AU2022203481B2 (en) 2023-10-19
BR122021026889A2 (fr) 2019-08-27
JP2024123011A (ja) 2024-09-10
BR112019010222A2 (pt) 2019-08-27
BR112019010222A8 (pt) 2022-11-22
JP2023002532A (ja) 2023-01-10
US20190308975A1 (en) 2019-10-10
AU2024200344B2 (en) 2025-11-06
MX2021011683A (es) 2021-10-22
CN110248948A (zh) 2019-09-17
CN116903624A (zh) 2023-10-20
MX2019006206A (es) 2019-08-14
KR102789662B1 (ko) 2025-04-03
MX2021011676A (es) 2021-10-22
IL266955B2 (en) 2023-09-01
CO2019006018A2 (es) 2019-06-19
AU2017366879A1 (en) 2019-05-30
US20250230164A1 (en) 2025-07-17
IL301470A (en) 2023-05-01
US11072614B2 (en) 2021-07-27
KR102561697B1 (ko) 2023-07-28
IL266955A (en) 2019-07-31
US20240043426A1 (en) 2024-02-08
US20210300930A1 (en) 2021-09-30
JP2019535836A (ja) 2019-12-12
MX386520B (es) 2025-03-19
US12269829B2 (en) 2025-04-08
CA3043502A1 (fr) 2018-06-07
EP3548497A1 (fr) 2019-10-09
AU2024200344A1 (en) 2024-02-08
AU2017366879B2 (en) 2022-02-24
AU2022203481A1 (en) 2022-06-16
KR20230117467A (ko) 2023-08-08
WO2018102315A1 (fr) 2018-06-07
IL266955B1 (en) 2023-05-01
EP3548497A4 (fr) 2020-09-02
AU2017366879C1 (en) 2022-08-11
CN110248948B (zh) 2023-07-28
US11773097B2 (en) 2023-10-03
KR20190086686A (ko) 2019-07-23
JP7148533B2 (ja) 2022-10-05

Similar Documents

Publication Publication Date Title
IL284874A (en) Valbenazine salts and polymorphs thereof
MA46973A (fr) Polymorphes de sépiaptérine et leurs sels
IL265166B (en) Anti-influenza virus pyrimidine derivatives
MA54910A (fr) Sels de pyridine et procédé
IL267530A (en) Polymorphs
LT3402792T (lt) Chinolin-2-ono dariniai
DK3558961T3 (da) Polymorfer
LT3457851T (lt) Sobetiromo dariniai
EP3564216A4 (fr) Dérivé pyrimidine
EP3383883A4 (fr) Sels de conjugués en cancéro-thérapie
DK3286260T3 (da) Polyolefinrør
EP3426159A4 (fr) Identification de structures anatomiques
PT3247711T (pt) Novos sais e polimorfos de scy-078
DK3372589T3 (da) Pyrimidinderivat
DE102016006280A8 (de) Flächengebilde
DK3380465T3 (da) Diaminopyridinderivativer
EP3546539A4 (fr) Corps sous forme de rouleau
EP3470085A4 (fr) Dialysat péritonéal biocompatible
MA50669A (fr) Nouveaux sels
EP3368527A4 (fr) Sels de palbociclib
FIC20170055I1 (fi) Nusinerseeni tai sen suolat
DE112017003625A5 (de) Difluorstilben-Derivate
ITUA20162617A1 (it) Avvolgibile
TH1501004946A (th) อนุพันธ์ 2-แอซิลอะมิโนไธอะโซล (2-acylaminothiazole) หรือเกลือของพวกมัน
ES1152358Y (es) Billetero